Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital, shared on his Twitter:
” My first ESMO23! So excited to move the field forward with novel therapies for patients with pMMR/MSS Colorectal Cancer.
BOT/BAL single 75 mg CTLA4- dose
NEST-1 trial next steps
Sun Oct 22, 2023, 7-9 pm Madrid, Spain
“Building upon the exceptional depth and pattern of response reported earlier OncoGene Journal. Link to full text ”
Source: Pashtoon Kasi/Twitter